Orion Biotechnology Successfully Completes Phase I Clinical Study of 0B-002H Topical Gel for HIV Prevention
Ottawa, Canada, April 30, 2020 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today